Skip to content

DHACM in Robotic Assisted Laparoscopic Prostatectomy (RALP)

A Prospective Randomized Clinical Trial Using Dehydrated Human Amnion/Chorion Membrane (dHACM) in Nerve Sparing Robotic Assisted Laparoscopic Radical Prostatectomy (RALP) - Effect on Potency Outcomes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02526173
Enrollment
230
Registered
2015-08-18
Start date
2015-10-01
Completion date
2018-06-21
Last updated
2018-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction

Brief summary

The investigators will examine the beneficial impacts of applying of dHACM on the preserved neurovascular bundles (cavernosal nerves) and the prostate bed during robotic assisted laparoscopic prostatectomy. Such application can result in promotion of soft tissue healing and reduction of inflammation at the operative site and thus an acceleration of return of potency regulating cavernosal nerves.

Detailed description

The overall objective of this study is to evaluate the effectiveness of dehydrated human amnion/chorion membrane (dHACM) in reducing neurovascular bundle inflammation in prostate cancer patients undergoing bilateral full nerve sparing robotic assisted laparoscopic radical prostatectomy (RALP). Specifically, this study compares potency outcomes in patients who had full nerve sparing RALP procedures with dHACM application to the neurovascular bundles to that of full nerve sparing RALP without dHACM application to neurovascular bundles. Patients will be randomized to one of two possible treatment groups: * Group 1 - Treatment Group ( Full Nerve Sparing RALP + AmnioFix®) * Group 2 - Control Group ( Full Nerve Sparing RALP alone)

Interventions

PROCEDURERALP using full nerve sparing technique

RALP using full nerve sparing technique

OTHERdHACM Application

2x12 sheet of dHACM applied to the neurovascular bundle

Sponsors

MiMedx Group, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
40 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Male subjects between the ages 40-70. 2. Primary diagnosis of prostate cancer requiring surgical intervention 3. Have a willingness to comply with follow-up examination 4. Have ability to provide full written consent 5. Primary diagnosis of untreated with clinically localized prostate cancer with Gleason score of 6, 7,8 or 9 6. Planned elective radical prostatectomy with bilateral full nerve sparing technique 7. Patients who currently have a pre-operative SHIM \> 19 8. Negative urinalysis within 7 days prior to date of surgery

Exclusion criteria

1. Has signs or symptoms of any other disease which could result in allograft failure, or has experienced graft failure in the past 2. Has any condition(s), which seriously compromises the subject's ability to participate in this study, or has a known history of poor adherence with medical treatment 3. Has comorbid conditions that can be confused with or can exacerbate the condition, including diabetes or Advanced atherosclerotic vascular disease 4. Is unable to sign or understand informed consent 5. Is unable to comply with penile rehabilitation, including oral 5-phosphodiesterase inhibitor 6. Has a history of drug or alcohol abuse within last 12 months 7. Has autoimmune disease or a known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV 8. Is allergic to Aminoglycoside antibiotics (such as Gentamicin and/or Streptomycin) 9. Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study 10. Patients currently enrolled in another study. Concurrent enrollment in another study is prohibited 11. Has had prior hormonal therapy such as Lupron or oral anti-androgens 12. Living outside of United States 13. Partial nerve sparing technique used during Radical Prostatectomy

Design outcomes

Primary

MeasureTime frameDescription
Potency as assessed by Sexual Health Inventory for Men (SHIM) Score12 monthsAs measured by SHIM
Return to sexual function12 monthsPatient directed questionnaire

Secondary

MeasureTime frameDescription
Continence12 monthsAs assessed by American Urological Association (AUA) score

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026